Ocugen to Present at NobleCon16 - Noble Capital Markets’ Sixteenth Annual Investor Conference
February 10 2020 - 7:30AM
Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on
discovering, developing and commercializing transformative
therapies to treat rare and underserved ophthalmic diseases, today
announced it will present at NobleCon16 - Noble Capital Markets’
Sixteenth Annual Investor Conference, to be held February 17-18,
2020 in Hollywood, Florida.
Sanjay Subramanian, Chief Financial Officer of Ocugen, will
highlight Ocugen’s ophthalmology pipeline, which includes small
molecules, novel biologics and a breakthrough modifier gene therapy
platform. Ocugen is currently conducting a Phase 3 clinical
trial for OCU300, its small molecule product candidate designed to
treat patients with ocular Graft versus Host Disease (oGVHD), with
topline results expected in the second half of 2020.
Presentation
Details:Date: Monday, February 17,
2020Time: 4:30 PM (Eastern
Time)Location: Hard Rock Hotel & Casino,
Terrace Ballroom D
A high-definition video webcast will be
accessible for 90 days following the presentation via the following
link: https://www.ir.ocugen.com.
About Ocugen, Inc. Ocugen, Inc. is a
clinical-stage biopharmaceutical company focused on discovering,
developing and commercializing transformative therapies to treat
the whole eye. Our Phase 3 small molecule drug candidate for oGVHD,
if approved, will be the first and only treatment for this orphan
disease. Our breakthrough modifier gene therapy platform has
the potential to treat multiple retinal diseases with one drug –
“one to many”. And our novel biologic product candidate aims
to offer better therapy to patients with underserved diseases such
as wet age-related macular degeneration, diabetic macular edema and
diabetic retinopathy. For more information, please visit
www.ocugen.com.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from the Company’s current expectations. These and other
risks and uncertainties are more fully described in our periodic
filings with the Securities and Exchange Commission (the “SEC”),
including the risk factors described in the section entitled “Risk
Factors” in the Company’s Quarterly Report on Form 10-Q filed with
the SEC on November 12, 2019. Any forward-looking statements that
the Company makes in this press release speak only as of the date
of this press release. Except as required by law, the Company
assumes no obligation to update forward-looking
statements contained in this press release whether as a result of
new information, future events or otherwise, after the date of this
press release.
Corporate Contact:
Ocugen, Inc.
Kelly Beck
kelly.beck@ocugen.com
+1 484-328-4698
Media Contact:
LaVoieHealthScience
Emmie Twombly
etwombly@lavoiehealthscience.com
+1 857-389-6042
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2023 to Apr 2024